dr. Luca Pagliaro (MD)

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that is currently treated with intensive chemotherapy. These treatments come with long-term harmful side-effects – particularly in children- including infertility, loss of intellectual capacity and the development of secondary tumors. Although prognosis has improved with combination chemotherapy, a significant number of T-ALL patients relapse and become refractory to intensive treatment, indicating the need for improved and targeted therapy.
By studying patient samples, our laboratory wants to understand the interaction better between the tumor cells and the chemotherapeutics that are currently used in the clinic. By characterizing the role of novel genes associated with T-ALL we aim to identify new therapeutic targets that are less toxic for the treatment of childhood cancer.
    

• Targeting oncogenic Notch signaling with SERCA inhibitors; Journal of Hematology and Oncology; 2021; PMID: 33407740
• Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia; Cell Chemical Biology; 2020; PMID: 32386594
• Targeting Notch Trafficking and Processing in Cancers; Cells; 2020; PMID: 33003595
• The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity; Leukemia; 2018; PMID: 29568096    
   

• Lab address: Center for Medical Genetics Ghent, Lab of Normal and Malignant Hematopoiesis, Medical Research Building 2 (entrance 38, 1st Floor, Room 110.007),  Corneel Heymanslaan 10, 9000 Ghent, Belgium
• Linkedin 
• THEC - Universita di Parma 
• Google Scholar      
• Luca Pagliaro is interested to receive invitations for presentations or talks